International Ophthalmology

, Volume 32, Issue 6, pp 583–584 | Cite as

Repositioning of dexamethasone intravitreal implant (Ozurdex®) migrated into the anterior chamber

  • José I. Vela
  • Jaume Crespí
  • David Andreu
Case Report


Ozurdex® (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex® into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical removal of the implant was avoided due to the absence of anterior complications and the loss of effectiveness of the drug delivery system. Repositioning of the implant to the posterior segment is described. This case illustrates the efficacy of this technique in cases of migration into the anterior chamber in eyes without corneal decompensation.


Dexamethasone intravitreal implant Complications Surgical technique Ozurdex® 


  1. 1.
    Pardo D, Francés E, Gallego R, Díaz-Llopis M (2011) Anterior chamber migration of dexamethasone intravitreal implant Ozurdex®. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-011-1802-x
  2. 2.
    Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A (2012) Wandering Ozurdex® implant. J Ophthalmic Inflamm Infect 2:1–5PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Department of OphthalmologyInstitut Condal d’OftalmologiaBarcelonaSpain
  2. 2.Department of OphthalmologyHospital de la Santa Creu i de Sant PauBarcelonaSpain

Personalised recommendations